Watch our video to learn how the Bruyère team developed each of the evidence-based deprescribing guidelines.
This video helps viewers understand:
- The rationale for evidence-based deprescribing guidelines
- The process used for developing the deprescribing guidelines
- The steps that a health care professional and patient need to go through to make and carry out safe deprescribing processes
Guidelines and Algorithms
Evidence-based deprescribing guidelines have been developed by or in collaboration with the Bruyère Research Institute for five classes of medications. Each guideline is accompanied by a decision-support algorithm, patient pamphlet, infographic and for some, a whiteboard video on how to use the algorithm.
Proton Pump Inhibitor (PPI)
Proton pump inhibitors – or PPIs – are a class of drugs used to treat heartburn, gastroesophageal reflux disease and gastric ulcers. PPIs reduce the production of acid by blocking the enzyme in the wall of the stomach that produces acid
- Proton Pump Inhibitor evidence-based deprescribing guideline (published in Canadian Family Physician)
- Proton Pump Inhibitor deprescribing algorithm
- Proton pump inhibitor deprescribing guideline information pamphlet
- Proton pump inhibitor deprescribing infographic
- Whiteboard video on using the Proton Pump Inhibitor deprescribing algorithm
Antihyperglycemics are a class of drugs used to treat diabetes. They work in a variety of ways to lower blood sugar.
- Antihyperglycemic deprescribing guideline (published in Canadian Family Physician)
- Antihyperglycemic deprescribing algorithm
- Antihyperglycemic deprescribing guideline information pamphlet
- Antihyperglycemic deprescribing infographic
- Whiteboard video on using the Antihyperglycemic deprescribing algorithm
Antipsychotics are a class of drugs sometimes used for behavioural and psychological symptoms of dementia and insomnia. They are primarily used to treat psychiatric disorders such as bipolar disorder and schizophrenia, among other disorders. Antipsychotics affect a variety of neurotransmitters in the brain. This results in a calming, relaxing effect, but can also produce sedation and affect balance.
- Antipsychotic deprescribing guideline (published in Canadian Family Physician)
- Antipsychotic deprescribing algorithm
- Antipsychotic deprescribing guideline information pamphlet
- Antipsychotic deprescribing infographic
- Whiteboard video on using the Antipsychotic Deprescribing Algorithm
Benzodiazepine Receptor Agonist (BZRA)
Benzodiazepine receptor agonists are a class of drugs also called hypnotics or sedatives that are commonly prescribed for insomnia, among other conditions. They appear to work by suppressing the activity of nerves. This results in a calming, relaxing effect but can also produce sedation and affect memory.
- Benzodiazepine Receptor Agonist deprescribing guideline (published in Canadian Family Physician)
- Benzodiazepine Receptor Agonist deprescribing algorithm
- Benzodiazepine and Z-Drug deprescribing guideline information pamphlet
- Benzodiazepine and Z-Drug deprescribing infographic
- Whiteboard video on using the Benzodiazepine Receptor Agonist deprescribing algorithm
Cholinesterase Inhibitors (ChEIs) and Memantine
Cholinesterase inhibitors and memantine are drugs used to treat the symptoms of dementia.
- Cholinesterase Inhibitors and Memantine deprescribing guidelines (published with the University of Sydney)
- Cholinesterase Inhibitors and Memantine deprescribing algorithm
Please use the above algorithms freely, with credit to the authors. The algorithms are not for commercial use and are licensed under a Creative Commons Attribution-Noncommercial-ShareAlike 4.0 International License; do not modify or translate without permission. Contact email@example.com for more information.
Translation and adaptations
Interested in translating the algorithms into other languages? Please read our translations policy here.
Want to adapt the algorithms to meet standards and guidelines of your health care setting? Please read our modification policy here.
To inquire about commercial licensing, (i.e. using the Bruyère Deprescribing Guidelines Research Team’s materials in textbooks, booklets, packages, etc. that are intended to be sold for profit) please email firstname.lastname@example.org.
In this section
- “Talking About Your Medications” Workshop Series
- Case Reports and Testimonials
- Deprescribing Guideline Symposium Resources
- Deprescribing Guidelines and Algorithms
- Deprescribing in Ontario Long-Term Care
- Deprescribing Information Pamphlets
- Deprescribing Webinars
- Frequently Asked Questions
- Helpful Links
- PPI Deprescribing Patient Decision Aid